Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-951 vs Ondansetron for PONV Prophylaxis
NCT04557189Phase 2Completed
- Sponsor
- Takeda
- Start
- Oct 2020
- Primary completion
- Mar 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of TAK-951 in postoperative nausea and vomiting (PONV), sponsored by Takeda. Started Oct 2020; status: completed.
02
Drugs
TAK-951
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on NCT04557189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04557189.